BiomX Inc. (NYSE:PHGE) on Tuesday announced that the U.S. Food and Drug Administration (FDA) is continuing its evaluation of the nebulizer device used for drug administration in the company's Phase 2b trial of BX004 in cystic fibrosis patients.PHGE shares are retreating from recent levels. See the complete data hereThe company is working with the third-party manufacturer to address recent FDA follow-up information requests in order to lift the FDA's clinical hold with respect to the trial.The FDA has placed ...